Patrick Chaltin is the Managing Director of the Centre for Drug Design and Discovery (CD3). Under his management, CD3 is performing multiple innovative drug discovery projects in different stages of development (hit identification, hit-to-lead and lead optimisation) and for different disease indications (HIV, HCV, Alzheimer, auto-immune disorders, cancer, etc.).
At the same time, he is active as senior IP officer at the IP unit of K.U.Leuven R&D, which he joined in 2002 and where he was responsible for the management and exploitation of the IP created by KULeuven researchers within the pharmaceutical field. In 2009 he became an official European patent attorney. During the past years, he successfully negotiated and finalised licenses on potential drugs discovered at the K.U.Leuven with several major and smaller pharmaceutical and biotechnology companies and he was a member of the deal flow committee of Capricorn Venture Partners for the analysis of new investment opportunities. He is also member of the Board of Directors of Okapi Sciences.
He studied Pharmaceutical Sciences and obtained a Ph.D. in this field at the laboratory of Medicinal Chemistry of the Rega Institute for Medical Research. Patrick Chaltin is co-author of several peer-reviewed scientific publications and is inventor on multiple patent applications in the drug discovery field.
The Centre for Drug Design and Discovery (CD3), a model for stimulating innovation in drug discovery ( 4.71 MB)
CD3 has been established in 2006 by KULeuven and EIF as an investment fund for the stimulation of innovative small molecule drug discovery and technology transfer in this field. This new model has to date delivered multiple new and innovative drug discovery projects and potential drugs for different disease indications. CD3 allows for collabrations with, investments in and licensing to SMEs and forms the basis for the creation of new SMEs. Obtaining funding for this new model is difficult, while the EIF constitutes a good partner for establishing this model.